NCT04494243View on ClinicalTrials.gov

A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

January 15, 2021

Study Completion Date

January 15, 2021

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

AD-214 10/600mg

1 tablet administered before the breakfast during 7 days

DRUG

Rabeprazole 10mg

1 tablet administered before the breakfast during 7 days

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT04494243 - A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole | Biotech Hunter | Biotech Hunter